Fig. 1

Plasma concentration versus time of TAM and NDTAM (upper panels) and 4-HTAM and END (lower panels) observed during a dosing interval of TAM therapy (20 mg/day) in all investigated TAM-treated breast cancer patients (n = 40). The value of 6 ng/ml END corresponds to the threshold associated with efficacy